J&J: encouraging results in multiple myeloma
(CercleFinance.com) - The Janssen pharmaceutical companies of Johnson & Johnson today announced top-line results from a phase 1b study of Tecvayli (teclistamab-cqyv) and talquetamab, showing a high overall response rate in patients with relapsed or refractory multiple myeloma (RRMM).
These results highlight the potential combinability of these two novel bispecific therapies, which target distinct antigens on myeloma cells.
The investigational combination immunotherapy regimen demonstrated an overall response rate of 86.6% (71/82) at all dose levels, and an overall response rate of 96.3% (26/27) in patients receiving the recommended Phase 2 regimen.
These data were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
These results highlight the potential combinability of these two novel bispecific therapies, which target distinct antigens on myeloma cells.
The investigational combination immunotherapy regimen demonstrated an overall response rate of 86.6% (71/82) at all dose levels, and an overall response rate of 96.3% (26/27) in patients receiving the recommended Phase 2 regimen.
These data were presented in an oral session at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting.
Copyright (c) 2023 CercleFinance.com. All rights reserved.